Clinical Trials Browser

alectinib × 90 days × Clear all

NCT05713006 2026-04-08

Alectinib Pharmacokinetic in Patients With NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05987644 2026-04-08

DURABLE

Phase 1/2 Recruiting

Brain Neoplasms, Lung Neoplasms

NCT06624059 2026-04-08

HORIZON 2

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07001384 2026-04-08

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

Lymphoma, Large-Cell, Anaplastic

NCT03737994 2026-04-07

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT04774718 2026-04-06

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Phase 1/2 Recruiting

Central Nervous System Neoplasms

NCT06862869 2026-04-06

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Carcinoma, Non-Small-Cell Lung

NCT04302025 2026-04-03

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04589845 2026-04-02

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Active not recruiting

920 enrolled 2 FDA

Other solid neoplasm

Solid Tumors

NCT06765109 2026-03-24

ALKAZAR

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT06354387 2026-03-19

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

187 enrolled 14 charts

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05170204 2026-03-06

HORIZON 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03194893 2026-02-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Phase 3 Active not recruiting

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT03456076 2026-01-30

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

257 enrolled 14 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms